About Tetralogic Pharmaceuticals (OTCMKTS:TLOG)
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Industry, Sector and Symbol
Trailing P/E Ratio-0.0167682926829268
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Frequently Asked Questions
What is Tetralogic Pharmaceuticals' stock symbol?
Tetralogic Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TLOG."
How were Tetralogic Pharmaceuticals' earnings last quarter?
Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) posted its earnings results on Thursday, February, 26th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.14. View Tetralogic Pharmaceuticals' Earnings History.
Who are some of Tetralogic Pharmaceuticals' key competitors?
Some companies that are related to Tetralogic Pharmaceuticals include OmniTek Engineering (OMTK), Horsehead (ZINCQ), Excel Maritime Carriers (EXMCQ), BG Medicine (BGMD), Alpha Natural Resources (ANRZQ), Blue Ridge Mountain Resources (MHRCQ), Affymax (AFFY), GSE (GSEH), Uni-Pixel (UNXLQ), Digiliti Money Group (DGLT), Glori Energy (GLRI), Atlas Resource Partners (ARPJQ), Quiksilver (ZQKSQ), Goodrich Petroleum (GDPMQ), DynaVox (DVOXQ), Education Management (EDMC), QF Liquidation (QTWWQ) and Thunderbird Resources Equity (GMXRQ).
Who are Tetralogic Pharmaceuticals' key executives?
Tetralogic Pharmaceuticals' management team includes the folowing people:
- Andrew L. Pecora M.D., Independent Chairman of the Board
How do I buy Tetralogic Pharmaceuticals stock?
Shares of Tetralogic Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tetralogic Pharmaceuticals' stock price today?
One share of Tetralogic Pharmaceuticals stock can currently be purchased for approximately $0.03.
How big of a company is Tetralogic Pharmaceuticals?
Tetralogic Pharmaceuticals has a market capitalization of $681,154.00. The biopharmaceutical company earns $-49,720,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.
How can I contact Tetralogic Pharmaceuticals?
Tetralogic Pharmaceuticals' mailing address is PO Box 1305, PAOLI, PA 19301-5305, United States. The biopharmaceutical company can be reached via phone at +1-610-8899900 or via email at [email protected]
MarketBeat Community Rating for Tetralogic Pharmaceuticals (TLOG)MarketBeat's community ratings are surveys of what our community members think about Tetralogic Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Earnings History and Estimates Chart
Tetralogic Pharmaceuticals (OTCMKTS TLOG) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Tetralogic Pharmaceuticals (OTCMKTS:TLOG)
No dividend announcements for this company have been tracked by MarketBeat.com
Tetralogic Pharmaceuticals (OTCMKTS TLOG) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.40%
Institutional Ownership Percentage: 0.02%
Tetralogic Pharmaceuticals (OTCMKTS TLOG) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/9/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||333,630||$0.17||$56,717.10|| |
|2/5/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||1,415,490||$0.18||$254,788.20|| |
|2/2/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||369,132||$0.19||$70,135.08|| |
|1/28/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||311,930||$0.28||$87,340.40|| |
|7/10/2015||Andrew L Pecora||Director||Buy||50,000||$2.68||$134,000.00|| |
|7/9/2015||Andrew L Pecora||Director||Buy||50,000||$2.40||$120,000.00|| |
|7/2/2015||Paul J Schmitt||Director||Buy||10,000||$2.34||$23,400.00|| |
|3/27/2015||Pete A Meyers||CFO||Buy||5,000||$4.35||$21,750.00|| |
|3/26/2015||J Kevin Buchi||CEO||Buy||5,000||$4.23||$21,150.00|| |
|1/7/2015||J Kevin Buchi||CEO||Buy||5,000||$5.04||$25,200.00|| |
|12/10/2014||Colin Glenn Begley||SVP||Buy||5,900||$6.16||$36,344.00|| |
|12/9/2014||J Kevin Buchi||CEO||Buy||5,000||$6.01||$30,050.00|| |
|12/4/2014||Pete A Meyers||CFO||Buy||1,034||$4.94||$5,107.96|| |
|12/2/2014||J Kevin Buchi||CEO||Buy||10,000||$4.99||$49,900.00|| |
|11/26/2014||Colin Glenn Begley||SVP||Buy||3,100||$4.86||$15,066.00|| |
|11/26/2014||Lesley Russell||COO||Buy||20,000||$4.90||$98,000.00|| |
|11/25/2014||Colin Glenn Begley||SVP||Buy||2,000||$4.85||$9,700.00|| |
|11/18/2014||J Kevin Buchi||CEO||Buy||10,000||$4.82||$48,200.00|| |
|11/17/2014||Andrew L Pecora||Director||Buy||20,000||$4.53||$90,600.00|| |
|11/12/2014||Peter A Meyers||CFO||Buy||5,000||$3.98||$19,900.00|| |
|11/11/2014||J Kevin Buchi||CEO||Buy||10,000||$3.93||$39,300.00|| |
|11/10/2014||Paul J Schmitt||Director||Buy||20,000||$4.10||$82,000.00|| |
|12/17/2013||J Kevin Buchi||CEO||Buy||285,714||$7.00||$1,999,998.00|| |
|12/17/2013||James N Woody||Director||Buy||261,427||$7.00||$1,829,989.00|| |
|12/17/2013||Peter A Meyers||CFO||Buy||142,857||$7.00||$999,999.00|| |
|12/17/2013||Ventures Vii Lp Healthcare||Major Shareholder||Buy||713,463||$7.00||$4,994,241.00|| |
Tetralogic Pharmaceuticals (OTCMKTS TLOG) News Headlines
Tetralogic Pharmaceuticals (OTCMKTS:TLOG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Income Statement, Balance Sheet and Cash Flow Statement
Tetralogic Pharmaceuticals (OTCMKTS TLOG) Stock Chart for Wednesday, January, 17, 2018